Citations

Clear

1325 citation(s) found for "Mayo, Angela".

Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.
Kumar, Shaji , Lacy, Martha Q. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Vaxman, Iuliana , Sidiqi, M Hasib , Saleh, Abdullah S. Al , Muchtar, Eli , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Leung, Nelson , Gonsalves, Wilson I. , Hogan, William J. , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 8516-8516

10.1200/jco.2020.38.15_suppl.8516 Get It

8516 Background: The role of induction therapy prior to autologous stem cell transplant (ASCT) in immunoglobulin light chain (AL) amyloidosis remains controversial. Data on the prognostic impact of response to induction in a transplanted cohort are lacking. The aim of this study was to assess the impact of response to induction therapy on survival in patients undergoing ASCT for AL amyloidosis. Methods: We conducted a retrospective study of all newly diagnosed AL amyloidosis patients who received induction prior to ASCT between January 2007 and August 2017 at Mayo Clinic, Rochester, Minnesota. Patients receiving only corticosteroids prior to transplant were excluded as were those with an involved light chain of less than 5 mg/dL (not measurable for response). Results: 134 patients met inclusion criteria. The median age at diagnosis was 60 (range 36-74) and 85 (63%) were men. The most commonly used induction regimen was proteasome inhibitor-based (73.1%, n=98). The overall response rate to induction was 83% (complete response 17%, very good partial response 30% and partial response 36%). With a median follow up of 56.5 months, the median PFS and OS was 48.5 months and not reached, respectively. Response depth to induction therapy was associated with improved PFS and OS and was independent of the bone marrow plasma cell percentage. The median PFS was not reached for patients achieving ≥VGPR prior to ASCT and 33.8 months for patient achieving PR or less (P=0.001). The median OS was longer in patients with deeper responses (not reached for patients achieving ≥VGPR vs. 128 months for patients achieving PR or less (P=0.02). On multivariable analysis, independent predictors of OS were melphalan conditioning dose (RR= 0.38; P=0.018) and depth of response prior to transplant (RR 2.52; P=0.039). Conclusions: Hematologic response prior to transplant predicts post-transplant outcomes in patients with AL amyloidosis. [Table: see text]
Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).
Allmer, Cristine, Yost, Kathleen J. , Warsame, Rahma , Thanarajasingam, Gita , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Thompson, Carrie A. , Kumar, Shaji , Sidana, Surbhi , Larson, Melissa C. , Dueck, Amylou C. , Cerhan, James R. , Paludo, Jonas , Rajkumar, S. Vincent , Habermann, Thomas M. , Lin, Yi , Gertz, Morie A. , Witzig, Thomas E. , Dispenzieri, Angela , Gonsalves, Wilson I.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e19112-e19112

10.1200/jco.2020.38.15_suppl.e19112 Get It

e19112 Background: We sought to study the longitudinal QOL, financial burden and perception of care (PoC) in patients with multiple myeloma (MM) or lymphoma (LYM) enrolled on CTs vs. those receiving standard care (Non-CT). Methods: QOL was evaluated using the FACT-G questionnaire (baseline, 1, 2, 3, 6 & 12 months). Financial burden was evaluated using 10 questions adapted from the MEPS survey and PoC was evaluated using 6 questions adapted from the CAHPS survey (baseline, 3, 6 & 12 months). Results: 35 (28%) of 123 enrolled patients were treated on CTs. Demographics, QOL and financial burden are shown in the Table. Baseline QOL scores were similar in CT vs non-CT groups. Age, gender and self-reported performance status were significantly associated with baseline QOL, while lines of therapy & cancer type were not. There were no significant differences in change in QOL vs. baseline in patients treated on CTs vs. non-CTs at 1, 2, 3, 6 and 12 months from baseline, including the total FACT-G score and the subdomains of functional, physical, emotional and social well-being. Within each group, there was a decline in QOL over the first 3 months, specifically physical WB, which gradually returned to baseline. Baseline answers to financial burden questions were similar, except patients on CTs reported less need for taking extended time-off from work (22% vs. 46%, p = 0.02). The only statistically significant difference in individual Qs over 1 year was ‘worry about having to pay large medical bills’ at the 6-month timepoint (CT: 0%, non-CT: 52%, p = 0.01). Using a composite score from 4 MEPS questions, financial burden over time was lower in the CT group, though the differences were not statistically significant. There were no significant differences in PoC at baseline, 3, 6 and 12 months in the two groups based on answers to each of the six questions adapted from the CAHPS survey. Conclusions: Over 1 year, patients on CTs experienced a similar QOL and perceived their care to be similar as non-CT patients. Financial burden was lower in the CT group, though differences were not statistically significant. [Table: see text]
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma
Mellors, Patrick , Binder, Moritz , Greipp, Patricia T. , Peterson, Jess F. , Jevremović, Dragan , Pearce, Kathryn E., Lacy, Martha Q. , Hayman, Suzanne R. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Kourelis, Taxiarchis , Warsame, Rahma , Lust, John A., Kyle, Robert A. , Kumar, Shaji , Mellors, Patrick W , Binder, Moritz , Peterson, Jess F , Jevremovic, Dragan , Greipp, Patricia T , Ketterling, Rhett P. , Baughn, Linda B. , Buadi, Francis K. , Gertz, Morie A. , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | May 22, 2020 | Volume: 4 | Issue: 10 | Pages: 2236-2244

10.1182/bloodadvances.2019001275 | PMID 32442300 Get It

AbstractMetaphase cytogenetic abnormalities, plasma cell proliferation index (PCPro), and gain 1q by fluorescence in situ hybridization (FISH) are associated with inferior survival in newly diagnosed multiple myeloma (MM) treated with novel agents; however, their role in risk stratification is unclear in the era of the revised International Staging System (R-ISS). The objective of this study was to determine if these predictors improve risk stratification in newly diagnosed MM when accounting for R-ISS and age. We studied a retrospective cohort of 483 patients with newly diagnosed MM treated with proteasome inhibitors and/or immunomodulators. On multivariable analysis, R-ISS, age, metaphase cytogenetic abnormalities (both in aggregate and for specific abnormalities), PCPro, and FISH gain 1q were associated with inferior progression-free (PFS) and overall survival (OS). We devised a risk scoring system based on hazard ratios from multivariable analyses and assigned patients to low-, intermediate-, and high-risk groups based on their cumulative scores. The addition of metaphase cytogenetic abnormalities, PCPro, and FISH gain 1q to a risk scoring system accounting for R-ISS and age did not improve risk discrimination of Kaplan-Meier estimates for PFS or OS. Moreover, they did not improve prognostic performance when evaluated by Uno’s censoring-adjusted C-statistic. Lastly, we performed a paired analysis of metaphase cytogenetic and interphase FISH abnormalities, which revealed the former to be insensitive for the detection of prognostic chromosomal abnormalities. Ultimately, metaphase cytogenetics lack sensitivity for important chromosomal aberrations and, along with PCPro and FISH gain 1q, do not improve risk stratification in MM when accounting for R-ISS and age.
Acquired Hemophilia A and Hashimoto’s Thyroiditis in a patient with Idiopathic Multicentric Castleman’s Disease: A Case report
Durmuş, Rana Berru , Rake, Elizabeth Cathcart-, Durani, Urshila , Marshall, Ariela L. , Dispenzieri, Angela , Habermann, Thomas M.

Mayo Clinic

No container title available | May 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.159012382.24851277 Get It

53-year-old male with iMCD developed hematoma at biopsy site. He was diagnosed with acquired hemophilia A and Hashimoto’s both were associated with iMCD. He has been in remission without recurrence of hemophilia after Rituximab 375 mg/M² weekly for 1 month, and 375 mg/M² every 2 months for maintenance.
Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease
Sidana, Surbhi , Murray, David , Dasari, Surendra , Willrich, Maria Alice V. , Snyder, Melissa R. , Kohlhagen, Mindy , Lust, John A., Kourelis, Taxiarchis , Kumar, Shaji , Murray, David L., Willrich, Maria A , Kourelis, Taxiarchis , Dispenzieri, Angela , Gertz, Morie A , Sidana, Surbhi , Go, Ronald S. , Muchtar, Eli , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | May 1, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1002/ajh.25843 | PMID 32356376 Get It

AL patients don’t dare go without dara
Dispenzieri, Angela

Mayo Clinic

Blood | April 30, 2020 | Volume: 135 | Issue: 18 | Pages: 1509-1510

10.1182/blood.2020005436 | PMID 32353125 Get It

Absolute Values of Serum Immunoglobulin Free Light Chains Predict for Survival in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant.
Lacy, Martha Q. , Katzmann, Jerry A., Abraham, Roshini S. , Hayman, Suzanne R. , Kumar, Shaji , Clark, Raynell, Kyle, Robert A. , Litzow, Mark R. , Inwards, David J. , Elliott, Michelle A. , Micallef, Ivana M., Ansell, S., Porrata, Luis F. , Johnston, Patrick B. , Zeldenrust, Steve R., Greipp, Philip R., Lust, John A., Russell, Steve R., Dispenzieri, Angela , Rajkumar, S. Vincent , Zeldenrust, Steven R., Witzig, Thomas E. , Gertz, Morie A.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 422-422

10.1182/blood.v106.11.422.422 Get It

Abstract Introduction: The immunoglobulin free light chain (FLC) is the precursor protein of amyloid in primary systemic amyloidosis (AL). Historically, the ability to monitor the amyloid protein precursor has been crude. There is now a test that reproducibly measures serum levels of FLC. We evaluated the utility of this assay in patients with AL undergoing peripheral blood stem cell transplant (PBSCT). Methods: Between March 1, 1996 and July 31, 2004, 98 patients with AL undergoing PBSCT had serial FLC measurements performed either prospectively or on stored sera. Patients who died before their 100 day evaluation were excluded because response could not be estimated. FLC levels were performed using Freelite™ reagents on a Dade-Behring Nephelometer. In order to pool the data of the monoclonal kappa and lambda patients, the clonal free light chain was considered the involved] immunoglobulin free light chain for the purpose of these analyses and is henceforth referred to as FLC. The prognostic effects of the initial concentration and the extent of reduction of monoclonal FLC on survival were evaluated. Results: Pre-transplant, 94% of patients had an abnormal FLC ratio, with a median involved FLC of 152 mg/L [15.2 mg/dL]. Only 14% of 98 patients had a “measurable” serum M-spike (i.e. ≥ 10 g/L [1 g/dL]) on electrophoresis with a median of 1 g/L [0.1 g/dL]. Ten patients have died of their disease during a median follow-up time of 19.5 months, range 3.3 to 103 months. The 2- year and 4-year estimated survivals are 92% and 76%, respectively. Using the 75th percentile value of pre-PBSCT FLC (382 mg/L [38.2 g/dL]) as a grouping variable, there was a significantly higher risk of death 5.4 (95% confidence interval 1.5–19.3) in the patient quartile with the highest baseline FLC. Baseline FLC correlated with serum cardiac troponin T levels (rho 0.51, p<0.0001), suggesting that high FLC levels are associated with more advanced disease. After PBSCT, the median percent reduction of FLC was 81%. The percent FLC reduction did not predict for survival, but the absolute level of FLC achieved after therapy did. The hazard ratio for death for not achieving a post-transplant FLC of 20 mg/L [2 mg/dL] post-transplant was 5.1 (95% confidence interval 1.1–24.1). Of 91 patients evaluable for complete response by EBMT criteria, 45 had a complete hematological response. Sixty-five percent of the patients achieving a FLC level of less than 20 mg/L [2 mg/dL] also had a complete hematologic response. Free light chain response as defined by a post transplant FLC level 20mg/L [2 mg/dL] or lower was a more powerful predictor of survival than complete hematologic response, as defined by the EBMT multiple myeloma criteria. Post-PBSCT FLC level only weakly predicted for organ response, but median follow-up for surviving patients is relatively short at 19.6 months. Conclusion: FLC measurements both pre- and post-PBSCT are important predictors of patient outcome.
Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.
Hayman, Suzanne R. , Lacy, Martha Q. , Geyer, Susan M. , Kabat, Brian, Zeldenrust, Steven R., Kumar, Shaji , Greipp, Philip R., Lust, John A., Kyle, Robert A. , Rajkumar, S. Vincent , Dispenzieri, Angela , Fonseca, Rafaël , Witzig, Thomas E. , Gertz, Morie A.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 781-781

10.1182/blood.v106.11.781.781 Get It

Abstract Purpose: Lenalidomide (CC-5013) is an analogue of thalidomide and a lead clinical compound in a new group of drugs called IMiDS® which have immunomodulatory properties. Lenalidomide has shown promising results in relapsed refractory myeloma. It has a markedly different side-effect profile compared to thalidomide, with significantly fewer non- hematologic adverse events; myelosuppression, especially neutropenia, is the most common toxicity. We report the results of a phase II trial using the combination of lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for newly diagnosed multiple myeloma. Patients and Methods: 34 patients (23 male and 11 female) were enrolled. Lenalidomide was given orally 25 mg daily on days 1–21 of a 28-day cycle. Dexamethasone was given orally at a dose of 40 mg daily on days 1–4, 9–12, 17–20 of each cycle. Patients were allowed to go off treatment after 4 cycles of therapy to pursue stem cell transplantation, but treatment beyond four cycles was permitted at the physician’s discretion. For patients continuing therapy beyond 4 months, the dose of dexamethasone was reduced to 40 mg on days 1–4 of each cycle. Objective response was defined as a decrease in serum monoclonal (M) protein by 50% or greater and a decrease in urine M protein by at least 90% or to a level less than 200 mg/24 hours, confirmed by two consecutive determinations at least 4 weeks apart. Sub-classification as very good partial response (VGPR) required in addition to criteria for partial response, >=90% reduction in serum M protein, 24 hour urine M protein less than or equal to 100 mg, and 5% or fewer plasma cells on bone marrow examination. All patients received aspirin (81 mg or 325 mg daily) as prophylaxis against DVT. Results: The median age was 64 years (range, 32–78). All patients were evaluable for response and toxicity. Thirty-one of 34 patients (91%) achieved an objective response to therapy, including 2 patients (6%) achieving a complete response (CR) and 11 patients (32%) achieving very good partial response. Of the 3 patients not achieving an objective response, two met criteria for minor response and one had stable disease. Responses were rapid; the median time to response was 1 month. Adequate stem cells (>3.0 million CD34 cells/kg body weight) were obtained in all patients who proceeded to autologous stem cell transplantation. Forty-seven percent of patients experienced grade 3 or higher non-hematologic toxicity, most commonly fatigue (15%), muscle weakness (6%), anxiety (6%), pneumonitis (6%) and rash (6%). One patient died on study, and this was attributed to infection unrelated to therapy; the patient had stopped all therapy for over a month before the fatal infection occurred. One patient developed a pulmonary embolism, but recovered with therapy; no other patient developed deep vein thrombosis or pulmonary embolism. Conclusion: Rev/Dex is highly active and well tolerated in the treatment of newly diagnosed multiple myeloma with overall responses in over 90% of patients including complete and very good partial responses in 38%. Two large cooperative group trials are currently testing Rev/Dex as initial therapy for multiple myeloma in the United States.
Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.
Naina, Harris, Lacy, Martha Q. , Kumar, Shaji , Greipp, Philip R., Dispenzieri, Angela , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3475-3475

10.1182/blood.v106.11.3475.3475 Get It

Abstract Background: Although thalidomide induced neuropathy has been described for decades, many features such as incidence, risk factors, severity and character of the neuropathy are not well defined. We retrospectively reviewed the incidence and clinical course of peripheral neuropathy in patients treated with thalidomide or thalidomide/dexamethasone (Thal/Dex) on a Phase II Mayo Clinic trial. Methods: Patients who participated in a Mayo Clinic Phase II trial of thalidomide in myeloma were studied. In this trial, patients with SMM and RMM received thalidomide 200 mg per day escalated as tolerated to a maximum of 800 mg/day. Patients with NMM received thalidomide 200 mg/day plus dexamethasone 40 mg/day orally on days 1–4, 9–12, 17–20 (odd cycles) and 40 mg/day days 1–4 (even cycles) repeated monthly. The incidence and clinical course of neuropathy was assessed by chart review. The study was approved by the Mayo Clinic Institutional Review Board. Results: All 113 patients (70 male, 43 female) treated on trial were studied; 31 patients with smoldering/indolent myeloma (SMM), 32 patients with relapsed/refractory myeloma (RMM) and 50 patients with newly diagnosed myeloma (NMM). Patients were accrued to the parent protocol from April 1999 through March 2002. The median age was 62 years (range, 36–78). The median duration of thalidomide therapy on protocol was 15 months in SMM, 6 months in RMM and 4 months in NMM. Overall, 63 patients (56 %) developed symptoms of peripheral neuropathy. The incidence of neuropathy was 77%, 50%, and 46% in patients with SMM, RMM, and NMM, respectively. Neuropathy worsened during the treatment phase with/without dose reduction or after cessation in 15%, remained stable in 52%, and improved in 27%. Overall grade of neuropathy was grade 1 in most pts; 11% of all patients had grade 2 neuropathy and 2% had grade 3 neuropathy. Predominant symptoms of neuropathy were tingling and numbness involving both upper limb and lower limbs. Small subsets of patients complained of hearing loss 6 patients), and erectile dysfunction (4 patients). Electromyographic studies and nerve conduction studies were performed in 11 patients; the most common finding was a length dependent axonal neuropathy. Conclusion: Peripheral neuropathy is an important and common adverse event with thalidomide therapy that often limits the dose and duration of treatment. Its incidence and severity are likely related to dose and duration of therapy.
Prevalence of Light-Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS) among Olmsted County, Minnesota Residents Aged 50 Years or Greater.
Kyle, Robert A. , Plevak, Matthew F., Clark, Raynell, Therneau, Terry M. , Melton, L. Joseph, Katzmann, Jerry A., Rajkumar, S. Vincent , Larson, Dirk R. , Bradwell, A.R. , Dispenzieri, Angela

Mayo Clinic

Blood | April 19, 2020 | Volume: 108 | Issue: 11 | Pages: 5060-5060

10.1182/blood.v108.11.5060.5060 Get It

Abstract Background: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder that carries a 1% per year risk of progression to multiple myeloma (MM) or related malignancy. The prevalence and natural history of MGUS, in which by definition intact immunoglobulin heavy chain (IgH) is expressed, has been well described. However, up to 20% of myeloma (MM) is characterized by complete lack of IgH expression (Light-chain MM); the prevalence of a corresponding precursor entity, light chain MGUS (LC-MGUS) has not been determined. We report the first prevalence estimates of LC-MGUS in the general population from a large, well-defined geographic population using modern laboratory techniques. Methods: The cohort for this study was derived from one previously assembled by us to estimate the prevalence of MGUS (N Engl J Med2006;354:1362-9). The original cohort used to estimate the prevalence of MGUS consisted of 21,463 of the 28,038 enumerated residents aged 50 or over of Olmsted County Minnesota as of January 1, 1995. The sensitive serum free light chain (FLC) assay (The Binding Site Limited, Birmingham, U.K.) was performed on stored serum samples from these 21,463 persons. IgH expression was determined by immunofixation on all FLC results that had an abnormal kappa/lambda ratio (<0.26 or >1.65). LC-MGUS was defined as the presence of an abnormal FLC ratio and a negative immunofixation for IgH expression. Results: Adequate stored serum samples were available in 20,733 (97%) of the 21,463 persons. To date, the FLC assay has been performed and results were available for analysis on samples from 16,637 persons. An abnormal FLC ratio was observed in 572 persons. IgH expression was detected in 255 of these cases on immunofixation; these persons are considered as having MGUS, and were excluded from the estimation of LC-MGUS prevalence. This resulted in 317 persons out of 16,637 who had an abnormal FLC ratio without evidence of IgH expression, resulting in an estimated prevalence of LC- MGUS of 2%. Of the 317 cases of LC-MGUS identified in this study, 217 were kappa and 100 were lambda; in 35 cases the presence of the corresponding monoclonal light chain was apparent on immunofixation. The median age of the cohort of LC-MGUS was 62 years; males=151, females =166. The involved FLC level ranged from 0.118–270.0 mg/dL. The FLC ratio ranged from 0.014–0.253 (lambda) and 1.67–511.01 (kappa). So far, progression to multiple myeloma has occurred in 4 patients, a rate much higher than what is expected based on the prevalence of myeloma in the general population. Two additional patients have developed CLL. Conclusions: LC-MGUS is prevalent in 2% of the general population aged 50 years of age or older. The natural history of this disorder needs to be determined.